ATOS * Stock Overview
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Atossa Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.50 |
| 52 Week High | US$38.35 |
| 52 Week Low | US$11.18 |
| Beta | 1.24 |
| 1 Month Change | -15.00% |
| 3 Month Change | 70.00% |
| 1 Year Change | 113.39% |
| 3 Year Change | -48.42% |
| 5 Year Change | n/a |
| Change since IPO | -54.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| ATOS * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 6.3% | 0% | 0% |
| 1Y | 113.4% | 0% | 0% |
Return vs Industry: ATOS * exceeded the MX Biotechs industry which returned -6.9% over the past year.
Return vs Market: ATOS * exceeded the MX Market which returned 2.7% over the past year.
Price Volatility
| ATOS * volatility | |
|---|---|
| ATOS * Average Weekly Movement | 15.5% |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: ATOS *'s share price has been volatile over the past 3 months.
Volatility Over Time: ATOS *'s weekly volatility (15%) has been stable over the past year, but is still higher than 75% of MX stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 12 | Steve Quay | www.atossatherapeutics.com |
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company’s lead drug candidate oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs.
Atossa Therapeutics, Inc. Fundamentals Summary
| ATOS * fundamental statistics | |
|---|---|
| Market cap | Mex$3.26b |
| Earnings (TTM) | -Mex$512.20m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.4x
P/E RatioIs ATOS * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATOS * income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$30.09m |
| Earnings | -US$30.09m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ATOS * perform over the long term?
See historical performance and comparison